Patrick R. O'Neil, EVP, Chief Legal Officer, and General Counsel at Ionis Pharmaceuticals (IONS), has demonstrated a consistent pattern of selling activity in the company’s stock over recent months, with no recent purchases recorded. Since September 2025, O'Neil has executed 12 sales totaling approximately $17.1 million, with the largest transactions occurring in late 2025 and early 2026. Notably, on October 2, 2025, he sold shares worth over $2.3 million and $2 million in separate transactions, followed by additional sales exceeding $1.7 million and $958,976 later that month. The trend continued into 2026, with disposals of $697,045 on January 16 and $516,153 on January 30, culminating in a $763,662 sale on March 9. Smaller transactions, including a $18,374 derivative disposition labeled as code "J," suggest a mix of outright stock sales and option-related activity.
O'Neil’s trading history reflects a clear divestment strategy, with no buys reported in the same period. The absence of recent acquisitions contrasts with his cumulative buy value of approximately $11.3 million across his tenure, indicating a shift toward reducing his position in IONS. The transactions, often paired with derivative adjustments (denoted by code "M"), suggest structured sales rather than sporadic disposals. While the filings do not disclose motives, the consistency and scale of the sales—particularly concentrated in late 2025 and early 2026—highlight a deliberate reduction in exposure to Ionis Pharmaceuticals stock.
AI-assisted summary